绿叶制药1类创新药若欣林?获澳门上市批准
4月7日，绿叶制药（02186）发布公告，宣布其自主研发的1类创新药若欣林®（盐酸托鲁地文拉法辛缓释片）已获得中国澳门药物监督管理局的上市批准，用于治疗抑郁症。若欣林®是中国首个拥有自主知识产权的用于治疗抑郁症的化药1类创新药，其临床前研究显示对5-羟色胺、去甲肾上腺素和多巴胺均具有再摄取抑制作用，进一步的研究证实其三重再摄取抑制作用。
自2022年11月在中国内地获批上市以来，若欣林®的疗效和安全性得到了临床的广泛认可，已服务超过3万名患者。预计到2024年底，若欣林®将首次纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》，这将有助于提升其创新可及性，造福更多患者。同时，若欣林®用于治疗广泛性焦虑障碍的3期临床试验也在进行中。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10